Biointron’s Q4 2025 antibody industry report aims to explore the events and trends of the biopharmaceutical industry in October, November, and December. This quarter, 5 novel monoclonal antibody drugs have been approved by the US, UK, and China.
Trastuzumab Botidotin
Sibeprenlimab (Voyxact)
Picankibart (Pecondle)
Depemokimab (Exdensur)
Narsoplimab (Yartemlea)
Q4 2025 saw various acquisitions, collaborations, and licensing agreements of up to USD$12 billion. Investment into antibody drug startups has focused on de novo proteins and bispecific ADCs.
Gain exclusive insights into current trends such as:
5 novel antibody drugs approved for the first time in Q4
Top 20 antibody drug deals, including acquisitions, licensing agreements, and collaborations of up to US$12B
Current research into antibody conjugate types: ADCs, ABCs, ISACs, ARCs, and ATCs
The landscape of psoriasis treatment
A list of antibody drugs with soon approaching approval action dates to keep an eye out for in Q1 2026
Biointron's Q3 2026 Antibody Industry Trends report aims to explore the events a……
Artificial intelligence (AI) can be used throughout the drug development process……
Peptides and antibodies have different strengths as therapeutic molecules. Pepti……
Therapeutic antibodies are often used to block receptors or neutralize soluble m……
You can also contact us on the Scientist and Science Exchange marketplaces.